Exosome Therapy Companies Lead the Way in Personalized Medicine
- Forecast for 6 months: Expect to see the completion of phase 1/2 trials for several exosome therapy candidates, including Aegle Therapeutics’ AGLE-102 and EXO Biologics’ EXOB-001, which could lead to the initiation of phase 2/3 trials and further advancements in the field.
- Forecast for 1 year: The global exosome therapeutics market is expected to grow by $234.7 million from 2024 to 2028, with several companies, including Aruna Bio and Evox Therapeutics, advancing their candidates through clinical trials and securing regulatory approvals.
- Forecast for 5 years: By 2029, exosome therapy is expected to become a mainstream treatment option for several diseases, including cancer and neurological disorders, with several companies, including Capricor Therapeutics and ILIAS Biologics, having multiple candidates in various stages of development.
- Forecast for 10 years: By 2034, the global exosome therapeutics market is expected to reach $1 billion, with exosome therapy becoming a standard treatment option for several diseases, and several companies, including Aegle Therapeutics and EXO Biologics, having established themselves as leaders in the field.
Tags: billion, cancer, development, industry, medicine, neurological
